Although the prognostic value of AR immunoreactivity in TNBC remains controversial, preclinical and clinical data have revealed that patients with ER-negative/AR-positive breast cancer might be candidates for treatment with AR antagonist [43]. Here, AR is linked to breast carcinoma.